Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

Mark R. Gilbert; John Kuhn; Kathleen R. Lamborn; Frank Lieberman; Patrick Y. Wen; Minesh Mehta; Timothy Cloughesy; Andrew B. Lassman; Lisa M. DeAngelis; Susan Chang; Michael Prados

doi:10.1007/s11060-011-0650-1

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

Mark R. Gilbert
, John Kuhn
, Kathleen R. Lamborn
, Frank Lieberman
, Patrick Y. Wen
, Minesh Mehta
, Timothy Cloughesy
, Andrew B. Lassman
, Lisa M. DeAngelis
, Susan Chang
, Michael Prados

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	106
DOIs	https://doi.org/10.1007/s11060-011-0650-1
State	Published - Jan 1 2012

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1007/s11060-011-0650-1License: Unspecified

Cite this

@article{2a1bdc70ed7d45169efbb44036ecfff5,

title = "Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery",

author = "Gilbert, \{Mark R.\} and John Kuhn and Lamborn, \{Kathleen R.\} and Frank Lieberman and Wen, \{Patrick Y.\} and Minesh Mehta and Timothy Cloughesy and Lassman, \{Andrew B.\} and DeAngelis, \{Lisa M.\} and Susan Chang and Michael Prados",

note = "Clinical Study - Patient Study Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the αvβ3 and αvβ5 integrins. Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models. This study was designed to evaluate the efficacy and tumor delivery of cilengitide in patients with recurrent glioblastoma.",

year = "2012",

month = jan,

day = "1",

doi = "10.1007/s11060-011-0650-1",

language = "American English",

volume = "106",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

AU - Gilbert, Mark R.

AU - Kuhn, John

AU - Lamborn, Kathleen R.

AU - Lieberman, Frank

AU - Wen, Patrick Y.

AU - Mehta, Minesh

AU - Cloughesy, Timothy

AU - Lassman, Andrew B.

AU - DeAngelis, Lisa M.

AU - Chang, Susan

AU - Prados, Michael

N1 - Clinical Study - Patient Study Cilengitide is a cyclic pentapeptide that is a specific inhibitor of the αvβ3 and αvβ5 integrins. Preclinical studies demonstrate antiangiogenic activity and anti-invasive activity in a number of glioma models. This study was designed to evaluate the efficacy and tumor delivery of cilengitide in patients with recurrent glioblastoma.

PY - 2012/1/1

Y1 - 2012/1/1

UR - https://link.springer.com/content/pdf/10.1007%2Fs11060-011-0650-1.pdf

U2 - 10.1007/s11060-011-0650-1

DO - 10.1007/s11060-011-0650-1

M3 - Article

VL - 106

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

Disciplines

Access to Document

Other files and links

Cite this